The insulin-like growth factors (fGFs) are important regulators of cell metabolism, differentiation, and pro¬ liferation (1, 2) . Since IGFs are secreted as they are produced, orderly delivery to the target tissues and ultimate bioactivity of these growth-promoting peptides depends, to a large extent, on a family of specific, high affinity, diversely functioning ÎGF binding proteins (IGFBPs [1, 2] ). The first of these proteins to be characterized, fGFBP-1, is produced primarily by liver, ovarian granulosa cells, and secretory or decidualized endometrium (3) (4) (5) . Although the physiological role of IGFBP- 1 has not yet been clearly defined, there is strong evidence from both in vivo and in vitro studies that IGFBP-1 is a potent inhibitor of IGF action (6) (7) (8) (9) .
Numerous clinical investigations have indicated that insulin plays a major role in the regulation of IGFBP-1.
Plasma levels of ÍGFBP-1 are elevated in patients with poorly controlled insulin-dependent diabetes mellitus (IDDM) and during fasting, and rapidly decline after a meal or with insulin treatment (10) (11) (12) (13) . We have demonstrated that peripheral insulin concentrations of 70-90 pmol/1 are sufficient to achieve maximal suppres¬ sion of fGFBP-1 production in vivo (10, 14) . Further- (17) (18) (19) . However, the effect of insulin dominates, both preventing and reversing dexamethasone-induced increases in IGFBP-1 gene transcription (17, 18) . In vivo rat studies are consistent with dual regulation of fGFBP-1 by insulin and glucocorticoids (20) (21) (22) . A role for glucocorticoids in regulating IGFBP-subjects, dexamethasone treatment resulted in compen¬ satory hyperinsulinemia and a decrease in plasma IGFBP-1 levels (23) . In another study, the normal early morning rise in plasma IGFBP-1 associated with over¬ night fasting was absent in patients with Cushing's syndrome (24) (21, 22) . Previous human studies indicated that high glucocorticoid levels were associated with reduced plasma IGFBP-1 levels (23, 24) . However, those studies may have been compromised by glucocorticoid-associated hyperinsulinemia. As in vitro studies have demon¬ strated, the suppressive effect of insulin on hepatic IGFBP-1 synthesis can override the stimulatory effect of glucocorticoids (17, 18 ). An essential component of the present protocol was the elimination of an insulin effect by use of a pancreatic clamp. With this technique we were able to maintain peripheral and portal insulin at sub-fasting concentrations, and well below levels that suppress hepatic fGFBP-1 production (10, 14) . Further¬ more, the relatively long study period enabled us to achieve equilibrium conditions for IGFBP-1 during saline infusion and to observe the stimulatory effect of cortisol. In vitro studies also showed that significant increases in IGFBP-1 protein in response to dexametha¬ sone required four to six hours (17, 19 (6) (7) (8) . Unterman and Phillips described glucocorticoid-induced serum inhibitors of ÍGF bioactivity, which appear to include IGFBP-1 (20, 30) . Moreover, acute infusion of fGFBP-1 has recently been shown to increase glucose levels (9) , raising the possibility that IGFBP-1 inhibits IGF-mediated glucose utilization. Thus, cortisol-induced increases in IGFBP-1 may contribute to the glucose intolerance seen in pathophysical conditions of glucocorticoid excess and insulinopenia. Additional studies will be needed to clarify the interrelationship of cortisol and ÍGFBP-1 and its influence on carbohydrate metab¬ olism.
